Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02574728 · ClinicalTrials.gov registry record · Phase 2
Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
A Phase 2 study of Cancer, sponsored by Emory University.
- Active
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 6
- Study locations
NCT02574728 is a Phase 2 study of Cancer that is active but no longer recruiting, run by Emory University. The registered enrollment target is 46 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT02574728, a Phase 2 study of Cancer, is active but no longer recruiting, sponsored by Emory University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study aims to determine the efficacy of daily sirolimus and celecoxib, with low dose etoposide alternating with cyclophosphamide for pediatric participants with relapsed or refractory tumors.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Sirolimus
- DRUG Etoposide
- DRUG Celecoxib
Study Locations (6)
Georgia
- Children's Healthcare of Atlanta-Egleston - Atlanta
- Children's Healthcare of Atlanta, Scottish Rite - Atlanta
Arizona
- Phoenix Children's Hospital - Phoenix
Delaware
- Nemours/Alfred I. duPont Hospital for Children - Wilmington
Missouri
- Children's Mercy Hospital - Kansas City
Virginia
- University of Virginia Health System - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2015-06 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02574728
The ClinicalTrials.gov registry entry for NCT02574728 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT02574728 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Georgia, Arizona, Delaware.
Frequently Asked Questions
What is clinical trial NCT02574728 about?
NCT02574728 is a clinical study titled "Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors". This study aims to determine the efficacy of daily sirolimus and celecoxib, with low dose etoposide alternating with cyclophosphamide for pediatric participants with relapsed or refractory tumors.
What is the current status of trial NCT02574728?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2015-06. Estimated completion is 2026-06.
What conditions does trial NCT02574728 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT02574728?
The interventions under investigation include: Cyclophosphamide (DRUG), Sirolimus (DRUG), Etoposide (DRUG), Celecoxib (DRUG).
Who is sponsoring clinical trial NCT02574728?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02574728 being conducted?
This trial has 6 study locations across Arizona, Delaware, Georgia, Missouri, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.